RT @BikovAndras: @fritsfranssen @ThoraxBMJ Exactly what we reported 2 years ago. https://t.co/s7VZThy2i4
@fritsfranssen @ThoraxBMJ Exactly what we reported 2 years ago. https://t.co/s7VZThy2i4
RT @BikovAndras: Analysing the results of the SUMMIT trial, we reported that FEV1 rather than FVC predict mortality in patients with #COPD…
Analysing the results of the SUMMIT trial, we reported that FEV1 rather than FVC predict mortality in patients with #COPD and #CVD. https://t.co/7HPSWFeA6V
RT @precisiondiagn4: RT @ATS_BSHSR: #FEV 1 Is a Stronger #Mortality #Predictor Than #FVC in Patients With #Moderate #COPD and With an Incre…
RT @ATS_BSHSR: #FEV 1 Is a Stronger #Mortality #Predictor Than #FVC in Patients With #Moderate #COPD and With an Increased Risk for #Cardiovascular #Disease #Pulmonary #Lung https://t.co/8pPtgdhYHz https://t.co/rbAajHIjMA
RT @ATS_BSHSR: #FEV 1 Is a Stronger #Mortality #Predictor Than #FVC in Patients With #Moderate #COPD and With an Increased Risk for #Cardio…
RT @ATS_BSHSR: #FEV 1 Is a Stronger #Mortality #Predictor Than #FVC in Patients With #Moderate #COPD and With an Increased Risk for #Cardio…
#FEV 1 Is a Stronger #Mortality #Predictor Than #FVC in Patients With #Moderate #COPD and With an Increased Risk for #Cardiovascular #Disease #Pulmonary #Lung https://t.co/KHkU9KQkQZ https://t.co/N0j3gRCHAt
RT @BikovAndras: Lung function and the risk for death in #COPD. Analysis of 16,485 participants in the SUMMIT trial. @ProfJVestbo, @Manches…
RT @BikovAndras: Lung function and the risk for death in #COPD. Analysis of 16,485 participants in the SUMMIT trial. @ProfJVestbo, @Manches…
RT @BikovAndras: Lung function and the risk for death in #COPD. Analysis of 16,485 participants in the SUMMIT trial. @ProfJVestbo, @Manches…
RT @BikovAndras: Lung function and the risk for death in #COPD. Analysis of 16,485 participants in the SUMMIT trial. @ProfJVestbo, @Manches…
RT @respiratorydec: FEV1 is a stronger #predictor for all-cause #mortality than FVC in moderate #COPD #patients with heightened #cardiovasc…
RT @respiratorydec: FEV1 is a stronger #predictor for all-cause #mortality than FVC in moderate #COPD #patients with heightened #cardiovasc…
RT @respiratorydec: FEV1 is a stronger #predictor for all-cause #mortality than FVC in moderate #COPD #patients with heightened #cardiovasc…
RT @respiratorydec: FEV1 is a stronger #predictor for all-cause #mortality than FVC in moderate #COPD #patients with heightened #cardiovasc…
FEV1 is a stronger #predictor for all-cause #mortality than FVC in moderate #COPD #patients with heightened #cardiovascular #risk and that subjects with moderate COPD have very different risks. https://t.co/Xv30iZsboA
RT @BikovAndras: Lung function and the risk for death in #COPD. Analysis of 16,485 participants in the SUMMIT trial. @ProfJVestbo, @Manches…
Lung function and the risk for death in #COPD. Analysis of 16,485 participants in the SUMMIT trial. @ProfJVestbo, @ManchesterBRC @GSK https://t.co/qHyXBIwj8o